SAN DIEGO–(BUSINESS WIRE)–Cytonus Therapeutics Inc., a biotechnology company developing new
platforms for delivering biologics, announced today that it will be
presenting preclinical data for its Cargocyte™ technology platform at
the American Association for Cancer Research (AACR) annual meeting March
29 – April 3, at the Georgia World Congress Center in Atlanta.
Cargocytes are engineered allogenic cell lines that can carry a variety
of payloads like small molecule compounds, gene editing therapies,
therapeutic RNAs, and powerful biologics such as immune modulating
cytokines, antibodies and oncolytic viruses.
“Cytonus Therapeutics will be presenting preclinical data from our
growing oncology pipeline that supports the versatility of our
Cargocytes as a groundbreaking allogeneic, off-the-shelf, immune-therapy
platform,” said Remo Moomiaie-Qajar, M.D., president and CEO of Cytonus.
“Our preclinical results in our Triple Negative Breast Cancer model
experiments are impressive and exciting. We are able to demonstrate that
40 percent of our animals being treated with our Cargocyte associated
IL-12 are showing no sign of disease more than 260 days post treatment
where as our control animals are dying typically 25 to 30 days into the
experiments. These experiments are still ongoing and our mice are doing
well. We have replicated these studies multiple times and have found the
pattern to exist.”
Details of the presentation:
Abstract Title: Cargocytes: A novel cell therapy platform to drive
Session Category: Immunology
Late-Breaking Research: Immunology 1
Session Date and Time:
Monday, April 1, 2019 8:00 AM – 12:00 PM
World Congress Center, Exhibit Hall B, Poster Section 41
Board Number: 12
Permanent Abstract Number: LB-067
will also be presenting at:
Association Society of Gene and
Cell Therapy (ASGCT), April 29-May 2, 2019 in Washington, D.C.
International Convention, June 3-6, 2019 in Philadelphia
Cytonus Therapeutics Inc.
Cytonus Therapeutics Inc. is a biopharmaceutical company developing a
next-generation Adoptive Cellular Transport platform called Cargocytes™.
The San Diego-based company’s proprietary Cargocyte™ platforms are
cellular-engineered transporters of a multiplicity of therapeutic
payloads to tissue in a selective, controllable and potent off-the-shelf
cellular therapy for the potential treatment of several diseases across
multiple therapeutic areas. Cytonus’ initial focus is to advance
Cargocyte™ candidates for the treatment of rare and difficult to treat
cancers and inflammatory diseases. For more information, visit www.cytonus.com
or follow us on LinkedIn.
Statements in this news release, which relate to other than strictly
historical facts, such as statements about Cytonus’ plans and
strategies, new and existing products and technologies, anticipated
clinical and regulatory pathways, and markets for its products are
forward-looking statements. The words “believe,” “expect,” “anticipate,”
“estimate,” “project,” and similar expressions identify forward-looking
statements that speak only as of the date hereof. Such statements
involve risks and uncertainties that could cause actual results to
differ materially from anticipated results due to many factors,
including regulatory and development risks. Cytonus undertakes no
obligation to publicly update or revise any forward-looking statements.
This news release is neither an offer to sell, nor the solicitation of
any offer to purchase, any security.